Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 3/20 | 0.70 |
| ▸ | GSK3B | P49841 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405452 | 0.87 | PAX8 (0.77) | PAX8GSK3AGSK3BMAPK1OPRK1 | |
| SCHEMBL12204760 | 0.77 | NPSR1 (0.75) | PAX8MAPK1OPRK1RAB9ANPSR1 | |
| SCHEMBL10195155 | 0.77 | HSP90AA1 (0.67) | PAX8MAPK1ALDH1A1KDM4EHSP90AA1 | |
| SCHEMBL6987406 | 0.76 | PAX8 (0.60) | PAX8MAPK1OPRK1RAB9ANPSR1 | |
| SCHEMBL6999642 | 0.76 | PAX8 (0.60) | PAX8MAPK1OPRK1RAB9ANPSR1 | |
| SCHEMBL6989868 | 0.76 | PAX8 (0.60) | PAX8MAPK1OPRK1RAB9ANPSR1 | |
| SCHEMBL28467060 | 0.75 | GSK3A (0.76) | PAX8GSK3AGSK3BNPSR1ALDH1A1 | |
| SCHEMBL3317084 | 0.75 | GSK3A (1.00) | PAX8GSK3AGSK3BMAPK1RAB9A | |
| SCHEMBL14678150 | 0.75 | HSP90AA1 (1.00) | PAX8GSK3AGSK3BMAPK1NPSR1 | |
| SCHEMBL6991542 | 0.75 | PAX8 (0.59) | PAX8MAPK1OPRK1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | disclosed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1830848-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
| WO-2000032598-A9 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | PAX8 3684/4885GSK3A 2452/4885GSK3B 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.